-
The first in the country! In 2020, TMB testing and clinical application expert consensus came out
Time of Update: 2020-11-30
3, TMB testing standardized 3.1 sample collection, treatment principle expert consensus: recommended to use the recent paraffin buried tumor tissue samples for tTMB testing, the testing organization should first complete pathological quality control and ensure that the number of malignant tumor cells can meet the detection requirements.
-
Hospitals across the country are cutting prices! The third batch was collected and landed
Time of Update: 2020-11-29
, according to Hu Jinglin, one of the key work in 2020, in addition to the implementation of the results of collection, but also to carry out the national organization of high-value medical supplies centralized procurement.
-
Clin Cancer Res: Multiple myeloma . . The "high dose" of amine is not loved
Time of Update: 2020-11-26
This is a multi-center, randomized, open-label clinical trial in which patients with multiple myeloma after ASCT and high doses of lenamin (25 mg/day) consolidation therapy (CT) were randomly assigned to the LenMT 25 mg/day group or 5 mg/day group.
-
Fda suspends clinical trials of CAR-T therapy UCTCS1 for multiple myeloma
Time of Update: 2020-11-26
Pharmaceutical company Cellectis announced today that the FDA has suspended melani-01 Phase I clinical trials designed to assess the effectiveness and safety of CAR-T therapy UCTCS1 in the treatment of recurring multiple myeloma (MM).
-
Blood: Do high-risk Philadelphia chromosomal-negative ALL adult patients need alllo-HSCT?
Time of Update: 2020-11-26
the ALL-HR-11 trial was to assess the outcome of chemotherapy or allo-HSCT in adult ALL patients with HR Ph-neg adults based on mrD levels after end-of-treatment induction and consolidation.
-
Blood: Post-HCT CD4-T cell reconstruction predicts survival prognostics in patients with acute GvHD
Time of Update: 2020-11-26
the non-recurrence mortality and overall survival rate of patients with CD4-IR iii-IV aGvHD were included in 591 patients (UMC/PMC 276 and MSK 315) within 100 days of HCT.
-
Blood: Recombinant FVIII drug Rurioctocog alfa pegol preventive treatment of haemophilia type A
Time of Update: 2020-11-26
PROPEL was a randomized Phase 3 trial that compared the safety and effectiveness of the two FVIII minimum levels in patients aged 12-65 years, with an annualized bleeding rate of ≥2, and PwHA severe patients who had previously received FVIII treatment.
-
Inventory: A selection of Lancet studies on November 21, 2020
Time of Update: 2020-11-26
effects of LDL elevation on myocardial infarction and atherosclerotic cardiovascular disease event risk in people aged 70-100 DOI:https://doi.org/10.1016/S0140- The results of previous studies at 6736 (20) 32233-9 showed that elevated LDL cholesterol was not associated with an increased risk of myocardial infarction and atherosclerosis cardiovascular disease in patients over 70 years of age, a view researchers recently tested among people aged 70-100.
-
Blood: Endotopic mesh-related degradation maintains the static and self-renewal of hematopoietic stem cells by limiting mTOR activity
Time of Update: 2020-11-25
recently, the latest issue of "ER associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity" reported that the protein quality controlled by endosperm-related degradation (ERAD) regulates the function of resting hematopoietic stem cells (HSCs).
-
Blood: Risk of recurrence after all-all child patients were deactivation of winteramidease
Time of Update: 2020-11-25
Based on most current treatments, the overall survival rate of ALL children has exceeded 90%, but the toxicity associated with winteramidease remains an important issue that, in addition to causing acute death, may also increase the risk of recurrence after drug suspension.
-
Blood: Nano monoantigen Caplacizumab is actually used in real clinical data in TTP patients
Time of Update: 2020-11-25
84 patients who received Caplacizumab treatment for TTP were treated with steroids and lytoxifen at the same time as PEX; the average time (3 days), PEX medium duration (7 days) and medium hospital stay (12 days) were all comparable to RCT data.
-
Blood: Characteristics of the evolution and diffusion of multiple myeloma clones
Time of Update: 2020-11-25
diffusion model of fluorescent MM cells showed that only a few clones that successfully adapted to the BM micro-environment could enter the bloodstream and be planted in long-range BMs.
-
The Lancet: Nuclear export inhibitor XPOVIO significantly prolongs the progression-free survival of patients with relapsed or refrectable multiple myeloma
Time of Update: 2020-11-25
most common emergency adverse events (AEs) for blood cell reduction and gastrointestinal symptoms, consistent with previous results reported in other selinexor studies.
-
Blood: Activated AKT triggers CLL by overactivated Notch1→ Richter conversion
Time of Update: 2020-11-25
in mice with E-TCL1 Akt compositional activation induced DLBCL esoteric in the E-TCL1 CLL mouse model, overactivation of the Akt gene led to the conversion of CLL to RT, significantly reducing survival and invasive lymphoma esoteric.
-
Blood: Salbonate enhances the anti-tumor activity of CRM1 inhibitors
Time of Update: 2020-11-25
KPT-330-CS significantly improves the mechanism of anti-tumor activity in patient samples, compared to the single use of KPT-330, K-CS can inhibit the expression of CRM1, RAD51 and thoracic nucleotide synthase proteins, thus more effectively inhibiting CRM1-mediated nuclear output, DNA damage repair, reducing synthesium synthesis, so that the cell cycle stalls in phase S, resulting in apoptosis.
-
The world's first nanoantibody, Caplacizumab, has again been approved by NICE to treat clotting disorders in patients with rare diseases, following the FDA and EMA
Time of Update: 2020-11-25
The Uk's National Institute for Health and Clinical Excellence (NICE) has approved Sanofi's Caplacizumab for the treatment of acquired thrombosis plateboard reduced cyanosis (aTTP), a rare and potentially life-threatening blood clotting disorder.
-
ATMP Europe recommended approval of five drugs at its November meeting
Time of Update: 2020-11-25
CHMP recommends that Phesgo (pertuzumab/trastuzumab) be used to treat early and metastasis HER2-positive breast cancer patients.
photo source: Baloxavir marboxil is recommended for the treatment of simple influenza aged 12 and over.
-
JAMA Oncology: Prognostic assessment of the deactivation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Time of Update: 2020-11-25
A new study published recently on JAMA Oncology called Assment of Outcomes After Stopping Tyrosine Kinase Patients With Chronic Myeloid Leukemia A Nonrandomized Clinical Trial assessed molecular recurrence (MRec) and prognostics (PROs) reported by patients after CML patients deactivated TKI.
-
Lancet oncol: RAF-MEK inhibitors are anti-tumor active in a variety of tumors carrying RAS/RAF mutations
Time of Update: 2020-11-06
CH5126766 (also known as VS-6766, formerly known as RO5126766) is a new MEK-pan-RAF inhibitor known to have anti-tumor activity in a variety of solid tumors; present study is intended to assess the safety and toxicity of ch5126766 intermittent administration programs, as well as the anti-tumor activity of the drug in patients with solid and multiple myelomas with RAS-RAF-MEK pathrain mutations.
-
The 8th National Hematology Conference, facing the lymphoma hematopoietic stem cell transplant application dilemma, how can blood doctors break the situation?
Time of Update: 2020-11-06
In China, data from Beijing Cancer Hospital show a five-year survival rate of 62%, close to the level of developed countries in Europe and the United States, mainly due to two aspects: first, the establishment and continuous improvement of the norms, including hematopoietic stem cell transplantation, overall treatment strategy, and second, a number of new drug clinical trials.
